Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + epirubicin + etoposide + ifosfamide
- Development stage
- Unknown
- Lead developer
- Universitätsklinikum Freiburg
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a multi-agent chemotherapy regimen combining four cytotoxic drugs—cisplatin, epirubicin, etoposide, and ifosfamide—primarily used for the treatment of non-small cell lung cancer (NSCLC), both limited-stage and extensive-stage disease. The regimen has been evaluated in phase I/II clinical trials for its feasibility and activity. The mechanism of action involves DNA damage induction through different pathways: cisplatin forms DNA crosslinks; epirubicin intercalates into DNA and inhibits topoisomerase II; etoposide inhibits topoisomerase II leading to DNA strand breaks; ifosfamide alkylates DNA bases causing strand breaks[1]. This combination is typically administered intravenously in cycles.
- Other names
- VIP-E regimenVIC-EPIE
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on cisplatin + epirubicin + etoposide + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + epirubicin + etoposide + ifosfamide.